Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.…
KALLELSE TILL EXTRA BOLAGSSTÄMMA I UPSALES TECHNOLOGY AB
Newbury Pharmaceuticals (STO: NEWBRY) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 1.945 SEK on 20 November 2026, up 25.5% over 52 weeks. Its 52-week range is 0.7600 SEK to 7.880 SEK: the price is 75.3% below the high and 155.9% above the low.
Its market capitalisation is 59.12M SEK.
Newbury Pharmaceuticals reports return on equity of -116.9%, an operating margin of -52.4% and revenue up 129.6% year over year.
It holds more cash than debt, a net cash position of 9.34M SEK. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.